Join
Live feed
·
NEWSReleasevia Quantisnow
First Wave BioPharma Inc. logo

First Wave BioPharma Changes Name to Entero Therapeutics, Company Advances Toward Phase 3 Clinical Trial With Lead Asset – Latiglutenase For The Treatment Of Celiac Disease

ByQuantisnow·Wall Street's wire, on your screen.
FWBI· First Wave BioPharma Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track FWBI (First Wave BioPharma Inc.) and more on Quantisnow.

First Wave BioPharma Changes Name to Entero Therapeutics, Company Advances Toward Phase 3 Clinical Trial With Lead Asset – Latiglutenase For The Treatment Of Celiac Disease | Quantisnow